It has been shown that patients with advanced HCC have an increased frequency of CD4+CD25+ regulatory T cells. These cells might suppress tumor-specific immune responses. Cyclophosphamide has been shown to reduce the frequency of CD4+CD25+ regulatory T cells. The aim of this study is to test if the treatment with cyclophosphamide leads to a decrease in the frequency of CD4+CD25+ regulatory T cells and to increase tumor specific immune responses in patients with advanced HCC.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
150 - 250 - 350 mg
Medizinische Hochschule Hannover
Hanover, Germany
Frequency of CD4+CD25+regulatory T cells
Time frame: within 8 weeks
Tumor specific immune responses
Time frame: within 12 weeks
Toxicity
Time frame: within 8 weeks
Function and Phenotype of CD4+CD25+ regulatory T cells
Time frame: within 12 weeks
Tumor response
Time frame: within 12 weeks
Survival
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.